MICROCHEMICAL JOURNAL-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=567637, encodeId=92ee56e637c2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这本杂志的效率特别高，已经在上面发表了两篇文章了，审稿1个月，之后修订之后在投最多两个星期就接受了！！！希望这个杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86db2074210, createdName=cuixuezi, createdTime=Tue Mar 05 10:52:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226884, encodeId=3d261226884f2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分析化学;电化学传感 经验分享：4月22号投稿 5月21号大修给了一个月时间 6月11号修回 6月16号录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6ca5420544, createdName=ms1000001896382660, createdTime=Thu Jun 16 20:37:29 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858695, encodeId=c97285869584, content=9.17投稿 12.2一审大修，催过一次 1.29 返修，一直reviewer invited 2.10 under review 3.15 二审，中间又催了一次 3.18 send to production 3.23 online 找审稿人等意见用了好长时间，一审三个审稿人问题十几条，写了8页的回复，幸好接受了，祝其他作者好运 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9055413985, createdName=ms248080445684567, createdTime=Mon Mar 23 16:52:42 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227493, encodeId=7000122e493a3, content=偏重的研究方向：生物传感器 经验分享：已经一个月了，还在with editor，正常吗？大佬们有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2978209804, createdName=ms5000001602762293, createdTime=Mon Jun 20 09:51:09 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208911, encodeId=196a120891167, content=偏重的研究方向：药物分析 经验分享：投稿两个月了，还是unde review，正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211102/d695345f72554a13a55e75f0e79318a1/781e6cdbec2944248d2c16407d999606.jpg, createdBy=05345686538, createdName=ms8000000326010509, createdTime=Wed Apr 06 09:52:37 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861259, encodeId=2591861259b8, content=1月14日投稿 4月1日返回修改 需要不数据学校开学后补了数据返回 5月31日录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Mon Jun 01 09:35:56 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095380, encodeId=bf6c109538037, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095379, encodeId=77cb10953e9f1, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857590, encodeId=4b7c85e5903e, content=2019-07-10 投稿 2019-09-04 大修，补了很多实验，所以花了很长时间，两个审稿人共有20几个意见 2019-12-28 返回 2020-01-15 录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb65414148, createdName=ms9921507639737342, createdTime=Tue Feb 18 11:03:16 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857263, encodeId=016d85e26351, content=1月6号投稿 1月8号送审 1月30号返回小修 2月4号接收 主编处理的稿件，速度快，审稿人意见中肯希望这个杂志涨涨涨！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcaa5413987, createdName=ms5469518383470847, createdTime=Tue Feb 04 14:47:03 CST 2020, time=2020-02-04, status=1, ipAttribution=)]

2019-03-05 cuixuezi

审稿速度:1.0 | 投稿命中率:50.0
经验分享：这本杂志的效率特别高，已经在上面发表了两篇文章了，审稿1个月，之后修订之后在投最多两个星期就接受了！！！希望这个杂志越来越好！

222 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=567637, encodeId=92ee56e637c2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这本杂志的效率特别高，已经在上面发表了两篇文章了，审稿1个月，之后修订之后在投最多两个星期就接受了！！！希望这个杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86db2074210, createdName=cuixuezi, createdTime=Tue Mar 05 10:52:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226884, encodeId=3d261226884f2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分析化学;电化学传感 经验分享：4月22号投稿 5月21号大修给了一个月时间 6月11号修回 6月16号录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6ca5420544, createdName=ms1000001896382660, createdTime=Thu Jun 16 20:37:29 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858695, encodeId=c97285869584, content=9.17投稿 12.2一审大修，催过一次 1.29 返修，一直reviewer invited 2.10 under review 3.15 二审，中间又催了一次 3.18 send to production 3.23 online 找审稿人等意见用了好长时间，一审三个审稿人问题十几条，写了8页的回复，幸好接受了，祝其他作者好运 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9055413985, createdName=ms248080445684567, createdTime=Mon Mar 23 16:52:42 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227493, encodeId=7000122e493a3, content=偏重的研究方向：生物传感器 经验分享：已经一个月了，还在with editor，正常吗？大佬们有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2978209804, createdName=ms5000001602762293, createdTime=Mon Jun 20 09:51:09 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208911, encodeId=196a120891167, content=偏重的研究方向：药物分析 经验分享：投稿两个月了，还是unde review，正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211102/d695345f72554a13a55e75f0e79318a1/781e6cdbec2944248d2c16407d999606.jpg, createdBy=05345686538, createdName=ms8000000326010509, createdTime=Wed Apr 06 09:52:37 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861259, encodeId=2591861259b8, content=1月14日投稿 4月1日返回修改 需要不数据学校开学后补了数据返回 5月31日录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Mon Jun 01 09:35:56 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095380, encodeId=bf6c109538037, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095379, encodeId=77cb10953e9f1, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857590, encodeId=4b7c85e5903e, content=2019-07-10 投稿 2019-09-04 大修，补了很多实验，所以花了很长时间，两个审稿人共有20几个意见 2019-12-28 返回 2020-01-15 录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb65414148, createdName=ms9921507639737342, createdTime=Tue Feb 18 11:03:16 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857263, encodeId=016d85e26351, content=1月6号投稿 1月8号送审 1月30号返回小修 2月4号接收 主编处理的稿件，速度快，审稿人意见中肯希望这个杂志涨涨涨！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcaa5413987, createdName=ms5469518383470847, createdTime=Tue Feb 04 14:47:03 CST 2020, time=2020-02-04, status=1, ipAttribution=)]

2022-06-16 ms1000001896382660

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：分析化学;电化学传感
经验分享：4月22号投稿
5月21号大修给了一个月时间
6月11号修回
6月16号录用

101 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=567637, encodeId=92ee56e637c2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这本杂志的效率特别高，已经在上面发表了两篇文章了，审稿1个月，之后修订之后在投最多两个星期就接受了！！！希望这个杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86db2074210, createdName=cuixuezi, createdTime=Tue Mar 05 10:52:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226884, encodeId=3d261226884f2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分析化学;电化学传感 经验分享：4月22号投稿 5月21号大修给了一个月时间 6月11号修回 6月16号录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6ca5420544, createdName=ms1000001896382660, createdTime=Thu Jun 16 20:37:29 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858695, encodeId=c97285869584, content=9.17投稿 12.2一审大修，催过一次 1.29 返修，一直reviewer invited 2.10 under review 3.15 二审，中间又催了一次 3.18 send to production 3.23 online 找审稿人等意见用了好长时间，一审三个审稿人问题十几条，写了8页的回复，幸好接受了，祝其他作者好运 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9055413985, createdName=ms248080445684567, createdTime=Mon Mar 23 16:52:42 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227493, encodeId=7000122e493a3, content=偏重的研究方向：生物传感器 经验分享：已经一个月了，还在with editor，正常吗？大佬们有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2978209804, createdName=ms5000001602762293, createdTime=Mon Jun 20 09:51:09 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208911, encodeId=196a120891167, content=偏重的研究方向：药物分析 经验分享：投稿两个月了，还是unde review，正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211102/d695345f72554a13a55e75f0e79318a1/781e6cdbec2944248d2c16407d999606.jpg, createdBy=05345686538, createdName=ms8000000326010509, createdTime=Wed Apr 06 09:52:37 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861259, encodeId=2591861259b8, content=1月14日投稿 4月1日返回修改 需要不数据学校开学后补了数据返回 5月31日录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Mon Jun 01 09:35:56 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095380, encodeId=bf6c109538037, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095379, encodeId=77cb10953e9f1, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857590, encodeId=4b7c85e5903e, content=2019-07-10 投稿 2019-09-04 大修，补了很多实验，所以花了很长时间，两个审稿人共有20几个意见 2019-12-28 返回 2020-01-15 录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb65414148, createdName=ms9921507639737342, createdTime=Tue Feb 18 11:03:16 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857263, encodeId=016d85e26351, content=1月6号投稿 1月8号送审 1月30号返回小修 2月4号接收 主编处理的稿件，速度快，审稿人意见中肯希望这个杂志涨涨涨！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcaa5413987, createdName=ms5469518383470847, createdTime=Tue Feb 04 14:47:03 CST 2020, time=2020-02-04, status=1, ipAttribution=)]

2020-03-23 ms248080445684567

9.17投稿
12.2一审大修，催过一次
1.29 返修，一直reviewer invited
2.10 under review
3.15 二审，中间又催了一次
3.18 send to production
3.23 online
找审稿人等意见用了好长时间，一审三个审稿人问题十几条，写了8页的回复，幸好接受了，祝其他作者好运

175 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=567637, encodeId=92ee56e637c2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这本杂志的效率特别高，已经在上面发表了两篇文章了，审稿1个月，之后修订之后在投最多两个星期就接受了！！！希望这个杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86db2074210, createdName=cuixuezi, createdTime=Tue Mar 05 10:52:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226884, encodeId=3d261226884f2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分析化学;电化学传感 经验分享：4月22号投稿 5月21号大修给了一个月时间 6月11号修回 6月16号录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6ca5420544, createdName=ms1000001896382660, createdTime=Thu Jun 16 20:37:29 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858695, encodeId=c97285869584, content=9.17投稿 12.2一审大修，催过一次 1.29 返修，一直reviewer invited 2.10 under review 3.15 二审，中间又催了一次 3.18 send to production 3.23 online 找审稿人等意见用了好长时间，一审三个审稿人问题十几条，写了8页的回复，幸好接受了，祝其他作者好运 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9055413985, createdName=ms248080445684567, createdTime=Mon Mar 23 16:52:42 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227493, encodeId=7000122e493a3, content=偏重的研究方向：生物传感器 经验分享：已经一个月了，还在with editor，正常吗？大佬们有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2978209804, createdName=ms5000001602762293, createdTime=Mon Jun 20 09:51:09 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208911, encodeId=196a120891167, content=偏重的研究方向：药物分析 经验分享：投稿两个月了，还是unde review，正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211102/d695345f72554a13a55e75f0e79318a1/781e6cdbec2944248d2c16407d999606.jpg, createdBy=05345686538, createdName=ms8000000326010509, createdTime=Wed Apr 06 09:52:37 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861259, encodeId=2591861259b8, content=1月14日投稿 4月1日返回修改 需要不数据学校开学后补了数据返回 5月31日录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Mon Jun 01 09:35:56 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095380, encodeId=bf6c109538037, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095379, encodeId=77cb10953e9f1, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857590, encodeId=4b7c85e5903e, content=2019-07-10 投稿 2019-09-04 大修，补了很多实验，所以花了很长时间，两个审稿人共有20几个意见 2019-12-28 返回 2020-01-15 录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb65414148, createdName=ms9921507639737342, createdTime=Tue Feb 18 11:03:16 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857263, encodeId=016d85e26351, content=1月6号投稿 1月8号送审 1月30号返回小修 2月4号接收 主编处理的稿件，速度快，审稿人意见中肯希望这个杂志涨涨涨！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcaa5413987, createdName=ms5469518383470847, createdTime=Tue Feb 04 14:47:03 CST 2020, time=2020-02-04, status=1, ipAttribution=)]

2022-06-20 ms5000001602762293

偏重的研究方向：生物传感器
经验分享：已经一个月了，还在with editor，正常吗？大佬们有这种情况吗

102 0

[GetPortalCommentsPageByObjectIdResponse(id=567637, encodeId=92ee56e637c2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这本杂志的效率特别高，已经在上面发表了两篇文章了，审稿1个月，之后修订之后在投最多两个星期就接受了！！！希望这个杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86db2074210, createdName=cuixuezi, createdTime=Tue Mar 05 10:52:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226884, encodeId=3d261226884f2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分析化学;电化学传感 经验分享：4月22号投稿 5月21号大修给了一个月时间 6月11号修回 6月16号录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6ca5420544, createdName=ms1000001896382660, createdTime=Thu Jun 16 20:37:29 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858695, encodeId=c97285869584, content=9.17投稿 12.2一审大修，催过一次 1.29 返修，一直reviewer invited 2.10 under review 3.15 二审，中间又催了一次 3.18 send to production 3.23 online 找审稿人等意见用了好长时间，一审三个审稿人问题十几条，写了8页的回复，幸好接受了，祝其他作者好运 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9055413985, createdName=ms248080445684567, createdTime=Mon Mar 23 16:52:42 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227493, encodeId=7000122e493a3, content=偏重的研究方向：生物传感器 经验分享：已经一个月了，还在with editor，正常吗？大佬们有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2978209804, createdName=ms5000001602762293, createdTime=Mon Jun 20 09:51:09 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208911, encodeId=196a120891167, content=偏重的研究方向：药物分析 经验分享：投稿两个月了，还是unde review，正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211102/d695345f72554a13a55e75f0e79318a1/781e6cdbec2944248d2c16407d999606.jpg, createdBy=05345686538, createdName=ms8000000326010509, createdTime=Wed Apr 06 09:52:37 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861259, encodeId=2591861259b8, content=1月14日投稿 4月1日返回修改 需要不数据学校开学后补了数据返回 5月31日录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Mon Jun 01 09:35:56 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095380, encodeId=bf6c109538037, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095379, encodeId=77cb10953e9f1, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857590, encodeId=4b7c85e5903e, content=2019-07-10 投稿 2019-09-04 大修，补了很多实验，所以花了很长时间，两个审稿人共有20几个意见 2019-12-28 返回 2020-01-15 录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb65414148, createdName=ms9921507639737342, createdTime=Tue Feb 18 11:03:16 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857263, encodeId=016d85e26351, content=1月6号投稿 1月8号送审 1月30号返回小修 2月4号接收 主编处理的稿件，速度快，审稿人意见中肯希望这个杂志涨涨涨！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcaa5413987, createdName=ms5469518383470847, createdTime=Tue Feb 04 14:47:03 CST 2020, time=2020-02-04, status=1, ipAttribution=)]

2022-04-06 ms8000000326010509

偏重的研究方向：药物分析
经验分享：投稿两个月了，还是unde review，正常吗？

103 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=567637, encodeId=92ee56e637c2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这本杂志的效率特别高，已经在上面发表了两篇文章了，审稿1个月，之后修订之后在投最多两个星期就接受了！！！希望这个杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86db2074210, createdName=cuixuezi, createdTime=Tue Mar 05 10:52:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226884, encodeId=3d261226884f2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分析化学;电化学传感 经验分享：4月22号投稿 5月21号大修给了一个月时间 6月11号修回 6月16号录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6ca5420544, createdName=ms1000001896382660, createdTime=Thu Jun 16 20:37:29 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858695, encodeId=c97285869584, content=9.17投稿 12.2一审大修，催过一次 1.29 返修，一直reviewer invited 2.10 under review 3.15 二审，中间又催了一次 3.18 send to production 3.23 online 找审稿人等意见用了好长时间，一审三个审稿人问题十几条，写了8页的回复，幸好接受了，祝其他作者好运 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9055413985, createdName=ms248080445684567, createdTime=Mon Mar 23 16:52:42 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227493, encodeId=7000122e493a3, content=偏重的研究方向：生物传感器 经验分享：已经一个月了，还在with editor，正常吗？大佬们有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2978209804, createdName=ms5000001602762293, createdTime=Mon Jun 20 09:51:09 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208911, encodeId=196a120891167, content=偏重的研究方向：药物分析 经验分享：投稿两个月了，还是unde review，正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211102/d695345f72554a13a55e75f0e79318a1/781e6cdbec2944248d2c16407d999606.jpg, createdBy=05345686538, createdName=ms8000000326010509, createdTime=Wed Apr 06 09:52:37 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861259, encodeId=2591861259b8, content=1月14日投稿 4月1日返回修改 需要不数据学校开学后补了数据返回 5月31日录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Mon Jun 01 09:35:56 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095380, encodeId=bf6c109538037, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095379, encodeId=77cb10953e9f1, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857590, encodeId=4b7c85e5903e, content=2019-07-10 投稿 2019-09-04 大修，补了很多实验，所以花了很长时间，两个审稿人共有20几个意见 2019-12-28 返回 2020-01-15 录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb65414148, createdName=ms9921507639737342, createdTime=Tue Feb 18 11:03:16 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857263, encodeId=016d85e26351, content=1月6号投稿 1月8号送审 1月30号返回小修 2月4号接收 主编处理的稿件，速度快，审稿人意见中肯希望这个杂志涨涨涨！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcaa5413987, createdName=ms5469518383470847, createdTime=Tue Feb 04 14:47:03 CST 2020, time=2020-02-04, status=1, ipAttribution=)]

2020-06-01 ms3860263520721591

1月14日投稿
4月1日返回修改
需要不数据学校开学后补了数据返回
5月31日录用

182 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=567637, encodeId=92ee56e637c2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这本杂志的效率特别高，已经在上面发表了两篇文章了，审稿1个月，之后修订之后在投最多两个星期就接受了！！！希望这个杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86db2074210, createdName=cuixuezi, createdTime=Tue Mar 05 10:52:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226884, encodeId=3d261226884f2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分析化学;电化学传感 经验分享：4月22号投稿 5月21号大修给了一个月时间 6月11号修回 6月16号录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6ca5420544, createdName=ms1000001896382660, createdTime=Thu Jun 16 20:37:29 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858695, encodeId=c97285869584, content=9.17投稿 12.2一审大修，催过一次 1.29 返修，一直reviewer invited 2.10 under review 3.15 二审，中间又催了一次 3.18 send to production 3.23 online 找审稿人等意见用了好长时间，一审三个审稿人问题十几条，写了8页的回复，幸好接受了，祝其他作者好运 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9055413985, createdName=ms248080445684567, createdTime=Mon Mar 23 16:52:42 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227493, encodeId=7000122e493a3, content=偏重的研究方向：生物传感器 经验分享：已经一个月了，还在with editor，正常吗？大佬们有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2978209804, createdName=ms5000001602762293, createdTime=Mon Jun 20 09:51:09 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208911, encodeId=196a120891167, content=偏重的研究方向：药物分析 经验分享：投稿两个月了，还是unde review，正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211102/d695345f72554a13a55e75f0e79318a1/781e6cdbec2944248d2c16407d999606.jpg, createdBy=05345686538, createdName=ms8000000326010509, createdTime=Wed Apr 06 09:52:37 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861259, encodeId=2591861259b8, content=1月14日投稿 4月1日返回修改 需要不数据学校开学后补了数据返回 5月31日录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Mon Jun 01 09:35:56 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095380, encodeId=bf6c109538037, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095379, encodeId=77cb10953e9f1, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857590, encodeId=4b7c85e5903e, content=2019-07-10 投稿 2019-09-04 大修，补了很多实验，所以花了很长时间，两个审稿人共有20几个意见 2019-12-28 返回 2020-01-15 录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb65414148, createdName=ms9921507639737342, createdTime=Tue Feb 18 11:03:16 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857263, encodeId=016d85e26351, content=1月6号投稿 1月8号送审 1月30号返回小修 2月4号接收 主编处理的稿件，速度快，审稿人意见中肯希望这个杂志涨涨涨！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcaa5413987, createdName=ms5469518383470847, createdTime=Tue Feb 04 14:47:03 CST 2020, time=2020-02-04, status=1, ipAttribution=)]

2021-12-28 乌云背后的幸福线

如何判断两种药物之间是协同作用还是相加作用？

113 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=567637, encodeId=92ee56e637c2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这本杂志的效率特别高，已经在上面发表了两篇文章了，审稿1个月，之后修订之后在投最多两个星期就接受了！！！希望这个杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86db2074210, createdName=cuixuezi, createdTime=Tue Mar 05 10:52:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226884, encodeId=3d261226884f2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分析化学;电化学传感 经验分享：4月22号投稿 5月21号大修给了一个月时间 6月11号修回 6月16号录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6ca5420544, createdName=ms1000001896382660, createdTime=Thu Jun 16 20:37:29 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858695, encodeId=c97285869584, content=9.17投稿 12.2一审大修，催过一次 1.29 返修，一直reviewer invited 2.10 under review 3.15 二审，中间又催了一次 3.18 send to production 3.23 online 找审稿人等意见用了好长时间，一审三个审稿人问题十几条，写了8页的回复，幸好接受了，祝其他作者好运 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9055413985, createdName=ms248080445684567, createdTime=Mon Mar 23 16:52:42 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227493, encodeId=7000122e493a3, content=偏重的研究方向：生物传感器 经验分享：已经一个月了，还在with editor，正常吗？大佬们有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2978209804, createdName=ms5000001602762293, createdTime=Mon Jun 20 09:51:09 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208911, encodeId=196a120891167, content=偏重的研究方向：药物分析 经验分享：投稿两个月了，还是unde review，正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211102/d695345f72554a13a55e75f0e79318a1/781e6cdbec2944248d2c16407d999606.jpg, createdBy=05345686538, createdName=ms8000000326010509, createdTime=Wed Apr 06 09:52:37 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861259, encodeId=2591861259b8, content=1月14日投稿 4月1日返回修改 需要不数据学校开学后补了数据返回 5月31日录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Mon Jun 01 09:35:56 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095380, encodeId=bf6c109538037, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095379, encodeId=77cb10953e9f1, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857590, encodeId=4b7c85e5903e, content=2019-07-10 投稿 2019-09-04 大修，补了很多实验，所以花了很长时间，两个审稿人共有20几个意见 2019-12-28 返回 2020-01-15 录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb65414148, createdName=ms9921507639737342, createdTime=Tue Feb 18 11:03:16 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857263, encodeId=016d85e26351, content=1月6号投稿 1月8号送审 1月30号返回小修 2月4号接收 主编处理的稿件，速度快，审稿人意见中肯希望这个杂志涨涨涨！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcaa5413987, createdName=ms5469518383470847, createdTime=Tue Feb 04 14:47:03 CST 2020, time=2020-02-04, status=1, ipAttribution=)]

2021-12-27 MS68862005

上传文章有什么要求？

111 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=567637, encodeId=92ee56e637c2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这本杂志的效率特别高，已经在上面发表了两篇文章了，审稿1个月，之后修订之后在投最多两个星期就接受了！！！希望这个杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86db2074210, createdName=cuixuezi, createdTime=Tue Mar 05 10:52:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226884, encodeId=3d261226884f2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分析化学;电化学传感 经验分享：4月22号投稿 5月21号大修给了一个月时间 6月11号修回 6月16号录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6ca5420544, createdName=ms1000001896382660, createdTime=Thu Jun 16 20:37:29 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858695, encodeId=c97285869584, content=9.17投稿 12.2一审大修，催过一次 1.29 返修，一直reviewer invited 2.10 under review 3.15 二审，中间又催了一次 3.18 send to production 3.23 online 找审稿人等意见用了好长时间，一审三个审稿人问题十几条，写了8页的回复，幸好接受了，祝其他作者好运 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9055413985, createdName=ms248080445684567, createdTime=Mon Mar 23 16:52:42 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227493, encodeId=7000122e493a3, content=偏重的研究方向：生物传感器 经验分享：已经一个月了，还在with editor，正常吗？大佬们有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2978209804, createdName=ms5000001602762293, createdTime=Mon Jun 20 09:51:09 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208911, encodeId=196a120891167, content=偏重的研究方向：药物分析 经验分享：投稿两个月了，还是unde review，正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211102/d695345f72554a13a55e75f0e79318a1/781e6cdbec2944248d2c16407d999606.jpg, createdBy=05345686538, createdName=ms8000000326010509, createdTime=Wed Apr 06 09:52:37 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861259, encodeId=2591861259b8, content=1月14日投稿 4月1日返回修改 需要不数据学校开学后补了数据返回 5月31日录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Mon Jun 01 09:35:56 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095380, encodeId=bf6c109538037, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095379, encodeId=77cb10953e9f1, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857590, encodeId=4b7c85e5903e, content=2019-07-10 投稿 2019-09-04 大修，补了很多实验，所以花了很长时间，两个审稿人共有20几个意见 2019-12-28 返回 2020-01-15 录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb65414148, createdName=ms9921507639737342, createdTime=Tue Feb 18 11:03:16 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857263, encodeId=016d85e26351, content=1月6号投稿 1月8号送审 1月30号返回小修 2月4号接收 主编处理的稿件，速度快，审稿人意见中肯希望这个杂志涨涨涨！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcaa5413987, createdName=ms5469518383470847, createdTime=Tue Feb 04 14:47:03 CST 2020, time=2020-02-04, status=1, ipAttribution=)]

2020-02-18 ms9921507639737342

2019-07-10 投稿
2019-09-04 大修，补了很多实验，所以花了很长时间，两个审稿人共有20几个意见
2019-12-28 返回
2020-01-15 录用

187 0

[GetPortalCommentsPageByObjectIdResponse(id=567637, encodeId=92ee56e637c2, content=审稿速度:1.0 | 投稿命中率:50.0 经验分享：这本杂志的效率特别高，已经在上面发表了两篇文章了，审稿1个月，之后修订之后在投最多两个星期就接受了！！！希望这个杂志越来越好！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=222, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=86db2074210, createdName=cuixuezi, createdTime=Tue Mar 05 10:52:00 CST 2019, time=2019-03-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1226884, encodeId=3d261226884f2, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：分析化学;电化学传感 经验分享：4月22号投稿 5月21号大修给了一个月时间 6月11号修回 6月16号录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=101, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d6ca5420544, createdName=ms1000001896382660, createdTime=Thu Jun 16 20:37:29 CST 2022, time=2022-06-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=858695, encodeId=c97285869584, content=9.17投稿 12.2一审大修，催过一次 1.29 返修，一直reviewer invited 2.10 under review 3.15 二审，中间又催了一次 3.18 send to production 3.23 online 找审稿人等意见用了好长时间，一审三个审稿人问题十几条，写了8页的回复，幸好接受了，祝其他作者好运 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=175, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d9055413985, createdName=ms248080445684567, createdTime=Mon Mar 23 16:52:42 CST 2020, time=2020-03-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1227493, encodeId=7000122e493a3, content=偏重的研究方向：生物传感器 经验分享：已经一个月了，还在with editor，正常吗？大佬们有这种情况吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=102, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2978209804, createdName=ms5000001602762293, createdTime=Mon Jun 20 09:51:09 CST 2022, time=2022-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1208911, encodeId=196a120891167, content=偏重的研究方向：药物分析 经验分享：投稿两个月了，还是unde review，正常吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=103, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211102/d695345f72554a13a55e75f0e79318a1/781e6cdbec2944248d2c16407d999606.jpg, createdBy=05345686538, createdName=ms8000000326010509, createdTime=Wed Apr 06 09:52:37 CST 2022, time=2022-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=861259, encodeId=2591861259b8, content=1月14日投稿 4月1日返回修改 需要不数据学校开学后补了数据返回 5月31日录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=182, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9195413982, createdName=ms3860263520721591, createdTime=Mon Jun 01 09:35:56 CST 2020, time=2020-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095380, encodeId=bf6c109538037, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=113, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Tue Dec 28 14:52:50 CST 2021, time=2021-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1095379, encodeId=77cb10953e9f1, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=111, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=bb142989248, createdName=MS68862005, createdTime=Mon Dec 27 14:52:50 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857590, encodeId=4b7c85e5903e, content=2019-07-10 投稿 2019-09-04 大修，补了很多实验，所以花了很长时间，两个审稿人共有20几个意见 2019-12-28 返回 2020-01-15 录用 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=187, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bdb65414148, createdName=ms9921507639737342, createdTime=Tue Feb 18 11:03:16 CST 2020, time=2020-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=857263, encodeId=016d85e26351, content=1月6号投稿 1月8号送审 1月30号返回小修 2月4号接收 主编处理的稿件，速度快，审稿人意见中肯希望这个杂志涨涨涨！ , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=194, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fcaa5413987, createdName=ms5469518383470847, createdTime=Tue Feb 04 14:47:03 CST 2020, time=2020-02-04, status=1, ipAttribution=)]

2020-02-04 ms5469518383470847

1月6号投稿
1月8号送审
1月30号返回小修
2月4号接收
主编处理的稿件，速度快，审稿人意见中肯希望这个杂志涨涨涨！

194 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务